| 000 | 01322 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250513115314.0 | ||
| 264 | 0 | _c19970807 | |
| 008 | 199708s 0 0 eng d | ||
| 022 | _a1087-0156 | ||
| 024 | 7 |
_a10.1038/nbt0597-410 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrower, V | |
| 245 | 0 | 0 |
_aBiogen wins Euro MS approval, but loses patents. _h[electronic resource] |
| 260 |
_bNature biotechnology _cMay 1997 |
||
| 300 |
_a410 p. _bdigital |
||
| 500 | _aPublication Type: News | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xtherapeutic use |
| 650 | 0 | 4 |
_aBiotechnology _xeconomics |
| 650 | 0 | 4 |
_aDrug Industry _xeconomics |
| 650 | 0 | 4 | _aEuropean Union |
| 650 | 0 | 4 | _aGlatiramer Acetate |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aInterferon beta-1a |
| 650 | 0 | 4 | _aInterferon beta-1b |
| 650 | 0 | 4 |
_aInterferon-beta _xtherapeutic use |
| 650 | 0 | 4 | _aIsrael |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xtherapy |
| 650 | 0 | 4 |
_aPatents as Topic _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aPeptides _xeconomics |
| 650 | 0 | 4 | _aPolymers |
| 650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
| 650 | 0 | 4 | _aUnited States |
| 773 | 0 |
_tNature biotechnology _gvol. 15 _gno. 5 _gp. 410 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/nbt0597-410 _zAvailable from publisher's website |
| 999 |
_c9113125 _d9113125 |
||